Related Experiment Video
Updated: Aug 19, 2025
Author Spotlight: Exploring ShiDuGao's Multi-Target Approach in Anus Eczema Treatment
Published on: January 12, 2024
Efficacy of abrocitinib for atopic dermatitis: a meta-analysis of randomized controlled trials
Daojun Zhang1, Guangqiao He1, Tian Qian1
1Department of Skin Plastic Surgery and Beauty, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Introduction:
The efficacy of abrocitinib for atopic dermatitis remains controversial.
Aim:
We conducted a systematic review and meta-analysis to explore the influence of abrocitinib versus placebo on the treatment of atopic dermatitis.
Material And Methods:
We searched PubMed, Embase, Web of Science, EBSCO, and Cochrane Library databases up to June 2021 for randomized controlled trials (RCTs) assessing the effect of abrocitinib versus placebo for patients with atopic dermatitis. This meta-analysis was performed using a random-effect model.
Results:
Four RCTs involving 932 patients were included in the meta-analysis. Overall, compared with the control group for atopic dermatitis, abrocitinib has a remarkably positive impact on IGA response (OR = 6.60; 95% CI: 4.41-9.87; p < 0.00001), EASI-75 (OR = 9.19; 95% CI: 6.20-13.61; p < 0.00001), EASI-90 (OR = 10.50; 95% CI: 5.54-19.93; p < 0.0001), NRS response (OR = 6.99; 95% CI: 4.43-11.01; p < 0.00001) and adverse events (OR = 1.76; 95% CI: 1.23-2.52; p = 0.002), but showed no obvious influence on serious adverse events (OR = 0.53; 95% CI: 0.20-1.44; p = 0.22).
Conclusions:
Abrocitinib exerts a favorable effect on the treatment of atopic dermatitis.
More Related Videos
09:32Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
Published on: September 26, 2019
06:47Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment
Published on: September 27, 2017
